SlideShare uma empresa Scribd logo
1 de 19
Anu.B
Intern at Biz & Legis
www.bizandlegis.com
Patent is an intellectual property tool that safe
guards the invention of an inventor.
The validity of patent is for 20 years from the
date of filing of patent application
Pharmaceutical derivatives are granted patent
if it possess the character novelty.
Pharmaceutical means of or relating to
pharmacy
As like other products, for obtaining patent the
molecule structure, function properties etc
have to be specified in detail
www.bizandlegis.com
WHY PATENTS?
1. Prevent others from commercially utilize
that invention
2. Encourage financial risk and long term
research
3. Patents guarantee dissemination of
information
www.bizandlegis.com
Novartis AG v. UOI decided on 1st April 2013
Facts of the case
Novartis is the world’s leading pharmaceutical
company filed patent application for its new
version of cancer drug.
The drug is called glivec and is very expensive.
Glivec was already in the market, however
they decided to seek a patent on a slightly
altered version potentially giving it longer
period of market exclusivity.
www.bizandlegis.com
The case hinged on s.3(d) of the Indian Patents
Act which does not allow patents of new
version of known drug molecules if they
make it more effective than before. In the
mean time many Indian companies produced
generic drugs at very cheap rate which was
consumed by 300000 people .
Whereas 16000 people use glivec. Generic
versions can be manufactured when the
product expires the patent.
www.bizandlegis.com
ISSUES INVOLVED
1. whether glivec is a patentable product?
2. Whether it involves ever greening?
JUDGEMENT
With the majority under the presence of
Aftab Alam .J. and Ranjana Prakash Desai .J.
the court held that the patent application is
rejected on the grounds that :
www.bizandlegis.com
1. Mere modification does not give novelty to
the product and the applied product has no
better effect than the already existing
drug.
2. If the application is allowed to grant patent
for glivec it becomes re-patenting and lie
within the purview of ever greening which
is prohibited under the Indian Patent Law.
3. Since the patent for the already existing
drug has expired manufacturing and selling
of generic versions within the country at
cheap rate.
www.bizandlegis.com
A majority of indian population uses generic
version of glivec at cheap rate and enjoy
the easy accessibility of medicine.
The judgment has paved a clear path to
establish and secure human rights by
complying right to health through this
judgment.
It can be proudly concluded that Human rights
win as giant pharma Novartis loses the
case.
www.bizandlegis.com
Inalienable fundamental rights to which a person is
inherently entitled simply because he/she is a
human being.
UDHR 1948
Substantive rights- 1. Right to life 2. Freedom
from torture 3. Freedom from slavery 4. Right to
fair trial 5. Freedom of speech 6. Freedom of
thought, conscience and religion 7. Freedom of
movement 8. Rights debates ( Right to keep and
bear arms, future generations, sexual
orientation and gender identity, trade, water,
reproductive rights and information and
communication technologies )
ICCPR 1966
ICESCR 1966
www.bizandlegis.com
RIGHT TO HEALTH
Recognized in the UDHR, ICESCR and Convention on
the Rights of Persons with Disabilities.
Art.25 of UDHR- Everyone has the right to a standard
of living and well being of himself and his family.
Preamble of WHO declares it to be a fundamental
right of every human being to enjoy the highest
attainable standards.
www.bizandlegis.com
Defined u/art. 12 of ICESCR
Impliedly involves right to access medicine,
right to treatment and precautionary
measures.
Accessibility increases when the price of
medicine is cheap, nation based production,
availability of alternative at cheap rates etc.
Accessibility decreases when price in high,
imported medicine and rules regarding the
exporting countries etc.
www.bizandlegis.com
GLIVEC GENERIC VERSION OF GLIVEC
Manufactured and
distributed by
Novartis, a foreign
company.
Expensive in nature.
Pack of 30 tablets costs
$ 1,100. Accessibility
is low.
16000 people in India
preferred glivec
Manufactured and
distributed by approved
local companies such as
NATCO.
Least expensive
Nexavar- generic version-
pack of 120 tablets
costs $ 1000.
Accessibility is high.
300000 people prefer
generic version
WHO WILL MEET THE HUMAN RIGHTS
EFFECTIVELY????
GLIVEC OR ITS GENERIC VERSION!!!!!
www.bizandlegis.com
The judgment is nothing but the rejection of
patent application of glivec filed by Novartis.
As the application is very related to ever
greening which is barred by Indian Patent
law, no injustice has been done to Novartis
by the judgment.
Since patent period has been expired,
encouragement of manufacturing of generic
version of the same is permissible and do not
amount to violation of law.
www.bizandlegis.com
Government shall take quick steps to increase
accessibility of these generic version and the
cheap rate of medicine enhance the mobility
and accessibility.
Cancer is a serious disease that may cause
death. Right to health being a human right is
clearly violated on death of people due to
this reason.
www.bizandlegis.com
Judgment makes it easier to extend the
accessibility of the generic drugs through its
extensible manufacturing and distribution.
Governmental steps can be smoothly adopted
and implemented for making the drug to
reach the nook and corner of the country.
It can be noted that the compulsory licensing
of the same drug would not increase its
accessibility .
www.bizandlegis.com
www.bizandlegis.com
The judgment of Novartis case can be regarded
as the most fruitful, viable and traceable
decision that meet the human rights to the
highest ends.
Other Judgments favorable of generic drug
manufacturers
Roche Pegasys case- November 2012
Januvia patent case- 2nd April 2013
www.bizandlegis.com
www.bizandlegis.com

Mais conteúdo relacionado

Mais procurados

Landmark case of Compulsory Licensing in India
Landmark case of Compulsory Licensing in IndiaLandmark case of Compulsory Licensing in India
Landmark case of Compulsory Licensing in India
KIRAN PATANGE
 
Intellectual Property Rights in India : An Overview
Intellectual Property Rights in India : An OverviewIntellectual Property Rights in India : An Overview
Intellectual Property Rights in India : An Overview
Dr. Kalpeshkumar L Gupta
 
Patent fights in pharmaceutical sector
Patent fights in pharmaceutical sectorPatent fights in pharmaceutical sector
Patent fights in pharmaceutical sector
Nitin Patel
 
IPR and Economic Development
IPR and Economic DevelopmentIPR and Economic Development
IPR and Economic Development
Ashutosh Sharma
 
Llm lecture ipr concept and theories [compatibility mode]
Llm lecture ipr concept and theories [compatibility mode]Llm lecture ipr concept and theories [compatibility mode]
Llm lecture ipr concept and theories [compatibility mode]
sanjeev kumar chaswal
 

Mais procurados (20)

Landmark case of Compulsory Licensing in India
Landmark case of Compulsory Licensing in IndiaLandmark case of Compulsory Licensing in India
Landmark case of Compulsory Licensing in India
 
Copyright ppt 1
Copyright ppt 1Copyright ppt 1
Copyright ppt 1
 
Infringement of patents and remedies
Infringement of patents and remediesInfringement of patents and remedies
Infringement of patents and remedies
 
Intellectual Property Rights in India : An Overview
Intellectual Property Rights in India : An OverviewIntellectual Property Rights in India : An Overview
Intellectual Property Rights in India : An Overview
 
Surrender and Revocation of Patents
Surrender and Revocation of PatentsSurrender and Revocation of Patents
Surrender and Revocation of Patents
 
Intellectual Property Rights in India - An Overview
Intellectual Property Rights in India - An OverviewIntellectual Property Rights in India - An Overview
Intellectual Property Rights in India - An Overview
 
Patent fights in pharmaceutical sector
Patent fights in pharmaceutical sectorPatent fights in pharmaceutical sector
Patent fights in pharmaceutical sector
 
Subject matter of Copyright (Case Laws)
Subject matter of Copyright (Case Laws)Subject matter of Copyright (Case Laws)
Subject matter of Copyright (Case Laws)
 
Compulsory licensing (patents)
Compulsory licensing (patents)Compulsory licensing (patents)
Compulsory licensing (patents)
 
TRIPS ppt
TRIPS pptTRIPS ppt
TRIPS ppt
 
Patent Law in India_What,How to get it regisgtered and protected
Patent Law in India_What,How to get it regisgtered and protectedPatent Law in India_What,How to get it regisgtered and protected
Patent Law in India_What,How to get it regisgtered and protected
 
Registration of trademark
Registration of trademarkRegistration of trademark
Registration of trademark
 
The Designs Act, 2000
The Designs Act, 2000 The Designs Act, 2000
The Designs Act, 2000
 
The patent act
The patent actThe patent act
The patent act
 
Trademark law ppt
Trademark law pptTrademark law ppt
Trademark law ppt
 
IPR and Economic Development
IPR and Economic DevelopmentIPR and Economic Development
IPR and Economic Development
 
Llm lecture ipr concept and theories [compatibility mode]
Llm lecture ipr concept and theories [compatibility mode]Llm lecture ipr concept and theories [compatibility mode]
Llm lecture ipr concept and theories [compatibility mode]
 
Rights and limitations of patentee
Rights and limitations of patenteeRights and limitations of patentee
Rights and limitations of patentee
 
Copyright board
Copyright boardCopyright board
Copyright board
 
Trade marks
Trade marksTrade marks
Trade marks
 

Destaque (6)

Case studies patent
Case studies patentCase studies patent
Case studies patent
 
Novartis CSR and marketing concept
Novartis CSR and marketing conceptNovartis CSR and marketing concept
Novartis CSR and marketing concept
 
Bayer vs Natco Case
Bayer vs Natco CaseBayer vs Natco Case
Bayer vs Natco Case
 
Basmati rice case study
 Basmati rice case study Basmati rice case study
Basmati rice case study
 
Patent infringement
Patent infringementPatent infringement
Patent infringement
 
Intellectual Property Rights
Intellectual Property RightsIntellectual Property Rights
Intellectual Property Rights
 

Semelhante a Patent Overview in Novartis Case ppt

Lec15 Patents and Intellectual Property
Lec15 Patents and Intellectual PropertyLec15 Patents and Intellectual Property
Lec15 Patents and Intellectual Property
Janet Stemwedel
 
Serious trouble to indian pharma innovation over patents
Serious trouble to indian pharma innovation over patentsSerious trouble to indian pharma innovation over patents
Serious trouble to indian pharma innovation over patents
Proglobalcorp India
 
Medical Cannabis Investor Tool
Medical Cannabis Investor ToolMedical Cannabis Investor Tool
Medical Cannabis Investor Tool
Joseph Wyse
 

Semelhante a Patent Overview in Novartis Case ppt (20)

Compulsory licensing in the light of novartis ag case and Bayer Corp case
Compulsory licensing in the light of novartis ag case and Bayer Corp caseCompulsory licensing in the light of novartis ag case and Bayer Corp case
Compulsory licensing in the light of novartis ag case and Bayer Corp case
 
Indian Patent Regime after 1995 amendments, NIB patent wars
Indian Patent Regime after 1995 amendments, NIB patent warsIndian Patent Regime after 1995 amendments, NIB patent wars
Indian Patent Regime after 1995 amendments, NIB patent wars
 
Patents and intellectual property
Patents and intellectual propertyPatents and intellectual property
Patents and intellectual property
 
Patent war case
Patent war casePatent war case
Patent war case
 
Lec15 Patents and Intellectual Property
Lec15 Patents and Intellectual PropertyLec15 Patents and Intellectual Property
Lec15 Patents and Intellectual Property
 
Basics of Life Science Patent Law
Basics of Life Science Patent LawBasics of Life Science Patent Law
Basics of Life Science Patent Law
 
Will Nexavar® (Sorafenib Tosylate) Become Unprecedented Case Study?
Will Nexavar® (Sorafenib Tosylate) Become Unprecedented Case Study? Will Nexavar® (Sorafenib Tosylate) Become Unprecedented Case Study?
Will Nexavar® (Sorafenib Tosylate) Become Unprecedented Case Study?
 
Patenting and regulatory requirements of natural products protection of plant...
Patenting and regulatory requirements of natural products protection of plant...Patenting and regulatory requirements of natural products protection of plant...
Patenting and regulatory requirements of natural products protection of plant...
 
Compulsory license
Compulsory licenseCompulsory license
Compulsory license
 
Pharmaceutical Patenting in India.
Pharmaceutical Patenting in India.Pharmaceutical Patenting in India.
Pharmaceutical Patenting in India.
 
Pharmaceutical patent
Pharmaceutical patent Pharmaceutical patent
Pharmaceutical patent
 
Comparative study of Patent laws In United States, Canada and Patent infringe...
Comparative study of Patent laws In United States, Canada and Patent infringe...Comparative study of Patent laws In United States, Canada and Patent infringe...
Comparative study of Patent laws In United States, Canada and Patent infringe...
 
Biosimilars: A U.S. Perspective
Biosimilars: A U.S. PerspectiveBiosimilars: A U.S. Perspective
Biosimilars: A U.S. Perspective
 
Para i iv orange book
Para i iv orange bookPara i iv orange book
Para i iv orange book
 
Rogowsky
RogowskyRogowsky
Rogowsky
 
Serious trouble to indian pharma innovation over patents
Serious trouble to indian pharma innovation over patentsSerious trouble to indian pharma innovation over patents
Serious trouble to indian pharma innovation over patents
 
hatchwaxmanact of generic product development
hatchwaxmanact of generic product developmenthatchwaxmanact of generic product development
hatchwaxmanact of generic product development
 
Drug Patency
Drug PatencyDrug Patency
Drug Patency
 
Medical Cannabis Investor Tool
Medical Cannabis Investor ToolMedical Cannabis Investor Tool
Medical Cannabis Investor Tool
 
Gene patenting
Gene patentingGene patenting
Gene patenting
 

Último

Último (20)

Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 

Patent Overview in Novartis Case ppt

  • 1. Anu.B Intern at Biz & Legis www.bizandlegis.com
  • 2. Patent is an intellectual property tool that safe guards the invention of an inventor. The validity of patent is for 20 years from the date of filing of patent application Pharmaceutical derivatives are granted patent if it possess the character novelty. Pharmaceutical means of or relating to pharmacy As like other products, for obtaining patent the molecule structure, function properties etc have to be specified in detail www.bizandlegis.com
  • 3. WHY PATENTS? 1. Prevent others from commercially utilize that invention 2. Encourage financial risk and long term research 3. Patents guarantee dissemination of information www.bizandlegis.com
  • 4. Novartis AG v. UOI decided on 1st April 2013 Facts of the case Novartis is the world’s leading pharmaceutical company filed patent application for its new version of cancer drug. The drug is called glivec and is very expensive. Glivec was already in the market, however they decided to seek a patent on a slightly altered version potentially giving it longer period of market exclusivity. www.bizandlegis.com
  • 5. The case hinged on s.3(d) of the Indian Patents Act which does not allow patents of new version of known drug molecules if they make it more effective than before. In the mean time many Indian companies produced generic drugs at very cheap rate which was consumed by 300000 people . Whereas 16000 people use glivec. Generic versions can be manufactured when the product expires the patent. www.bizandlegis.com
  • 6. ISSUES INVOLVED 1. whether glivec is a patentable product? 2. Whether it involves ever greening? JUDGEMENT With the majority under the presence of Aftab Alam .J. and Ranjana Prakash Desai .J. the court held that the patent application is rejected on the grounds that : www.bizandlegis.com
  • 7. 1. Mere modification does not give novelty to the product and the applied product has no better effect than the already existing drug. 2. If the application is allowed to grant patent for glivec it becomes re-patenting and lie within the purview of ever greening which is prohibited under the Indian Patent Law. 3. Since the patent for the already existing drug has expired manufacturing and selling of generic versions within the country at cheap rate. www.bizandlegis.com
  • 8. A majority of indian population uses generic version of glivec at cheap rate and enjoy the easy accessibility of medicine. The judgment has paved a clear path to establish and secure human rights by complying right to health through this judgment. It can be proudly concluded that Human rights win as giant pharma Novartis loses the case. www.bizandlegis.com
  • 9. Inalienable fundamental rights to which a person is inherently entitled simply because he/she is a human being. UDHR 1948 Substantive rights- 1. Right to life 2. Freedom from torture 3. Freedom from slavery 4. Right to fair trial 5. Freedom of speech 6. Freedom of thought, conscience and religion 7. Freedom of movement 8. Rights debates ( Right to keep and bear arms, future generations, sexual orientation and gender identity, trade, water, reproductive rights and information and communication technologies ) ICCPR 1966 ICESCR 1966 www.bizandlegis.com
  • 10. RIGHT TO HEALTH Recognized in the UDHR, ICESCR and Convention on the Rights of Persons with Disabilities. Art.25 of UDHR- Everyone has the right to a standard of living and well being of himself and his family. Preamble of WHO declares it to be a fundamental right of every human being to enjoy the highest attainable standards. www.bizandlegis.com
  • 11. Defined u/art. 12 of ICESCR Impliedly involves right to access medicine, right to treatment and precautionary measures. Accessibility increases when the price of medicine is cheap, nation based production, availability of alternative at cheap rates etc. Accessibility decreases when price in high, imported medicine and rules regarding the exporting countries etc. www.bizandlegis.com
  • 12. GLIVEC GENERIC VERSION OF GLIVEC Manufactured and distributed by Novartis, a foreign company. Expensive in nature. Pack of 30 tablets costs $ 1,100. Accessibility is low. 16000 people in India preferred glivec Manufactured and distributed by approved local companies such as NATCO. Least expensive Nexavar- generic version- pack of 120 tablets costs $ 1000. Accessibility is high. 300000 people prefer generic version
  • 13. WHO WILL MEET THE HUMAN RIGHTS EFFECTIVELY???? GLIVEC OR ITS GENERIC VERSION!!!!! www.bizandlegis.com
  • 14. The judgment is nothing but the rejection of patent application of glivec filed by Novartis. As the application is very related to ever greening which is barred by Indian Patent law, no injustice has been done to Novartis by the judgment. Since patent period has been expired, encouragement of manufacturing of generic version of the same is permissible and do not amount to violation of law. www.bizandlegis.com
  • 15. Government shall take quick steps to increase accessibility of these generic version and the cheap rate of medicine enhance the mobility and accessibility. Cancer is a serious disease that may cause death. Right to health being a human right is clearly violated on death of people due to this reason. www.bizandlegis.com
  • 16. Judgment makes it easier to extend the accessibility of the generic drugs through its extensible manufacturing and distribution. Governmental steps can be smoothly adopted and implemented for making the drug to reach the nook and corner of the country. It can be noted that the compulsory licensing of the same drug would not increase its accessibility . www.bizandlegis.com
  • 18. The judgment of Novartis case can be regarded as the most fruitful, viable and traceable decision that meet the human rights to the highest ends. Other Judgments favorable of generic drug manufacturers Roche Pegasys case- November 2012 Januvia patent case- 2nd April 2013 www.bizandlegis.com